Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19033679 | ANTIBODIES TARGETING IL3 | January 2025 | May 2025 | Allow | 4 | 1 | 1 | No | No |
| 18988612 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18979795 | ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE | December 2024 | May 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18772062 | TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOF | July 2024 | October 2024 | Allow | 3 | 1 | 0 | No | No |
| 18642478 | APPLICATION OF A NANOBODY TARGETING ON IL-6RA | April 2024 | January 2025 | Allow | 9 | 2 | 0 | No | No |
| 18593108 | ANTI-HUMAN INTERLEUKIN-33 MONOCLONAL ANTIBODY AND USE THEREOF | March 2024 | March 2025 | Allow | 12 | 2 | 0 | No | No |
| 18429738 | Method for Producing an Active Hepatocyte Growth Factor (HGF) | February 2024 | May 2025 | Allow | 16 | 1 | 0 | No | No |
| 18448054 | Heparin-Associated Polypeptides and Uses Thereof | August 2023 | May 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18339094 | ANTIGEN-BINDING MOLECULES AND USES THEREOF | June 2023 | April 2024 | Allow | 9 | 1 | 1 | No | No |
| 18322927 | HEAVY CHAIN ONLY ANTIBODIES TO PDGF | May 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18311771 | ANTI-CD28 X ANTI-PSMA ANTIBODIES | May 2023 | January 2024 | Allow | 9 | 1 | 0 | No | No |
| 18311082 | LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF | May 2023 | October 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18307729 | COMPOSITIONS | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18304598 | ANTI C-MET ANTIBODIES | April 2023 | May 2025 | Allow | 25 | 1 | 1 | No | No |
| 18172987 | ANTI-CD28 X ANTI-PSMA ANTIBODIES | February 2023 | January 2025 | Allow | 23 | 2 | 1 | No | No |
| 18165515 | EGFR x CD28 MULTISPECIFIC ANTIBODIES | February 2023 | May 2025 | Allow | 27 | 0 | 0 | No | No |
| 18164351 | IL10 RECEPTOR BINDING MOLECULES AND METHODS OF USE | February 2023 | July 2024 | Allow | 17 | 2 | 1 | No | No |
| 18018448 | IL12 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE | January 2023 | December 2024 | Allow | 23 | 4 | 1 | No | No |
| 18160355 | METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASE | January 2023 | November 2024 | Allow | 22 | 1 | 0 | No | No |
| 18006831 | IL10RA BINDING MOLECULES AND METHODS OF USE | January 2023 | January 2025 | Allow | 24 | 4 | 1 | Yes | No |
| 18017838 | IL10Ra/IL2Ry SYNTHETIC CYTOKINES | January 2023 | March 2025 | Allow | 26 | 4 | 1 | No | No |
| 18017836 | IL2RB/IL2RG SYNTHETIC CYTOKINES | January 2023 | November 2024 | Abandon | 22 | 3 | 1 | No | No |
| 18068977 | CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES | December 2022 | December 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18065504 | DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES | December 2022 | January 2024 | Abandon | 13 | 0 | 1 | No | No |
| 18077137 | Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof | December 2022 | June 2025 | Allow | 30 | 2 | 0 | No | No |
| 18071057 | FULLY HUMANIZED ANTI-PLATELET FACTOR 4 ANTIBODIES THAT TREAT HEPARIN-INDUCED THROMBOCYTOPENIA | November 2022 | October 2024 | Allow | 22 | 2 | 0 | No | No |
| 17990497 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | September 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17990515 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | October 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17990460 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | August 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17990492 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | August 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17990478 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | August 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17990507 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | October 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17990438 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | November 2022 | September 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17818798 | COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | August 2022 | January 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17850135 | ANTI-ACTH ANTIBODIES AND USE THEREOF | June 2022 | March 2025 | Allow | 32 | 1 | 1 | No | No |
| 17850339 | CYSTEINE LINKED NANOBODY DIMERS | June 2022 | April 2025 | Allow | 34 | 2 | 1 | No | No |
| 17807939 | ARTHRITIS TREATMENT | June 2022 | June 2024 | Allow | 24 | 1 | 0 | No | No |
| 17842904 | ANTI-ANGPT2 ANTIBODIES | June 2022 | May 2024 | Allow | 23 | 1 | 0 | No | No |
| 17831398 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | June 2022 | October 2024 | Allow | 29 | 2 | 1 | No | No |
| 17777021 | TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOF | May 2022 | September 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17737343 | A Method for Producing An Active Hepatocyte Growth Factor (HGF) | May 2022 | June 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17724639 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | April 2022 | February 2023 | Abandon | 10 | 1 | 1 | No | No |
| 17719496 | IMMUNOGLOBULIN VARIABLE DOMAINS | April 2022 | March 2023 | Allow | 11 | 3 | 0 | No | No |
| 17702890 | MONOCLONAL ANTIBODIES TO ANGIOTENSIN-(1-12), COMPOSITIONS INCLUDING THE SAME, AND METHODS OF USE THEREOF | March 2022 | March 2025 | Allow | 36 | 3 | 1 | Yes | No |
| 17699925 | ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE | March 2022 | June 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17678861 | METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASE | February 2022 | November 2022 | Allow | 9 | 2 | 0 | No | No |
| 17592381 | Cancer Antigen Peptide | February 2022 | October 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17592375 | Cancer Antigen Peptide | February 2022 | September 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17592384 | Cancer Antigen Peptide | February 2022 | October 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17586620 | METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | January 2022 | November 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17583503 | HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORS | January 2022 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17579376 | Humanized Anti-VEGF Monoclonal Antibody | January 2022 | March 2024 | Allow | 26 | 2 | 0 | No | No |
| 17562499 | IMMUNOGLOBULIN VARIABLE DOMAINS | December 2021 | June 2022 | Allow | 5 | 1 | 0 | No | No |
| 17559808 | ANTI-ANGPTL 3/8 COMPLEX ANTIBODIES AND METHODS OF USING THE SAME | December 2021 | August 2024 | Allow | 32 | 2 | 0 | No | No |
| 17556193 | Modulation of Heparin-Binding Epidermal Growth Factor Activity for Tympanic Membrane Healing | December 2021 | March 2024 | Allow | 60 | 2 | 0 | No | No |
| 17539335 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS | December 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17528378 | RELAXIN FUSION POLYPEPTIDES AND USES THEREOF | November 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17453894 | TREATMENT OF PSYCHIATRIC CONDITIONS | November 2021 | August 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17501430 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | October 2021 | July 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17450872 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | October 2021 | March 2024 | Abandon | 29 | 2 | 1 | Yes | No |
| 17498262 | FUSION PROTEINS WITH EXTENDED SERUM HALF LIFE | October 2021 | December 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17481938 | COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES | September 2021 | December 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17469044 | ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE | September 2021 | August 2023 | Allow | 23 | 1 | 0 | No | No |
| 17466276 | ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE | September 2021 | May 2023 | Allow | 20 | 0 | 1 | No | No |
| 17462795 | MONOSPECIFIC AND BISPECIFIC ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF | August 2021 | March 2024 | Allow | 31 | 2 | 1 | No | No |
| 17412066 | NOVEL IGFR-LIKE 2 RECEPTOR AND USES THEREOF | August 2021 | January 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17407774 | FGFR3 ANTIBODIES AND METHODS OF USE | August 2021 | August 2022 | Allow | 12 | 2 | 1 | Yes | No |
| 17407012 | Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists | August 2021 | May 2025 | Abandon | 45 | 2 | 1 | No | Yes |
| 17397121 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | August 2021 | May 2025 | Allow | 46 | 2 | 1 | No | Yes |
| 17395800 | COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS | August 2021 | September 2024 | Allow | 37 | 2 | 1 | No | No |
| 17381537 | EPCAM ANTIBODY AND EPCAM-CAR-T CELLS | July 2021 | October 2024 | Allow | 39 | 0 | 1 | No | No |
| 17379909 | Method for Treating a Cancer Based on Inflammatory Subtype Thereof | July 2021 | November 2024 | Allow | 40 | 2 | 1 | No | No |
| 17378557 | MODIFIED FIBROBLAST GROWTH FACTORS FOR THE TREATMENT OF OCULAR DISORDERS | July 2021 | April 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17341325 | HEAVY CHAIN ONLY ANTIBODIES TO PDGF | June 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17335355 | Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders | June 2021 | October 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17240218 | FUSION POLYPEPTIDES AND METHODS OF USE | April 2021 | April 2025 | Allow | 48 | 3 | 1 | No | No |
| 17235653 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRING | April 2021 | May 2023 | Allow | 25 | 1 | 0 | No | No |
| 17233083 | HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEIN | April 2021 | August 2024 | Allow | 40 | 2 | 0 | No | No |
| 17230289 | ANTI-FLT3 ANTIBODIES AND COMPOSITIONS | April 2021 | November 2024 | Allow | 43 | 3 | 1 | No | No |
| 17216273 | OXIDIZED CARDIOLIPIN AS A PRO-INFLAMMATORY FACTOR | March 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17215163 | IMMUNOGLOBULIN VARIABLE DOMAINS | March 2021 | February 2022 | Allow | 10 | 2 | 1 | No | No |
| 17215121 | IMMUNOGLOBULIN VARIABLE DOMAINS | March 2021 | June 2022 | Allow | 14 | 4 | 1 | No | No |
| 17215039 | IMMUNOGLOBULIN VARIABLE DOMAINS | March 2021 | January 2022 | Allow | 10 | 2 | 1 | No | No |
| 17208483 | HEPATOCYTE GROWTH FACTOR FRAGMENTS THAT FUNCTION AS POTENT MET RECEPTOR AGONISTS AND ANTAGONISTS | March 2021 | July 2024 | Abandon | 39 | 3 | 0 | No | No |
| 17208292 | TIE2-BINDING AGENTS AND METHODS OF USE | March 2021 | July 2023 | Allow | 28 | 1 | 1 | No | No |
| 17205663 | ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE | March 2021 | December 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 17205573 | ENDOGLIN POLYPEPTIDES AND USES THEREOF | March 2021 | October 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17199810 | ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF | March 2021 | April 2023 | Allow | 26 | 1 | 1 | No | No |
| 17191651 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | March 2021 | March 2022 | Abandon | 13 | 2 | 0 | No | No |
| 17270987 | AFUCOSYLATED ANTIBODIES AND MANUFACTURE THEREOF | February 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17168055 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | February 2021 | February 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17163892 | ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS | February 2021 | October 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17154366 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | January 2021 | February 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17154340 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | January 2021 | March 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17149570 | PROPHYLACTIC AGENT, ONSET-SUPPRESSING AGENT OR THERAPEUTIC AGENT FOR PROGRESSIVE IMMUNE DEMYELINATING DISEASES | January 2021 | August 2024 | Allow | 43 | 3 | 0 | Yes | No |
| 17130152 | BIO-MIMETIC FORMULATION | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17255254 | ANTI-FLT-1 ANTIBODIES IN TREATING BRONCHOPULMONARY DYSPLASIA | December 2020 | July 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17127600 | FGF21 Mimetic Antibodies and Uses Thereof | December 2020 | February 2023 | Allow | 26 | 1 | 0 | No | No |
| 17253372 | AFFINITY CARRIER USING MUTANT VHH ANTIBODY | December 2020 | September 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17252525 | BI-AND TRI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF | December 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEN, MARIANNE P.
With a 5.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALLEN, MARIANNE P works in Art Unit 1647 and has examined 1,182 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner ALLEN, MARIANNE P's allowance rate of 52.1% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALLEN, MARIANNE P receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ALLEN, MARIANNE P is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by ALLEN, MARIANNE P. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.6% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 49.9% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 73.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 80.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 69.4% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.1% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.4% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.